Brazil’s regulatory agency, Anvisa, has announced that proposals to fast-track the licensing-assessment of a large proportion of applications for clinical trials of drugs and medical devices have received approved1.
Pending the formal publication of the enacted resolution by Anvisa and the precise detail of the policy, the government has issued a statement confirming that applications involving trials already approved in the EU, US, Japan, Australia or Canada will be fast-tracked, said Anvisa…
